Rise in Viral Infections Drives Growth in the Oral Antiviral Market: 2021-2031 Forecast
September 21, 2023 06:59 ET
|
Research and Markets
Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com announces a comprehensive analysis of the Oral Antiviral Market, projecting a promising CAGR of 2.1% from 2022 to 2031. The "Oral...
Oral Antiviral Market Is Predicted to Reach $43.39 Billion by 2031: Allied Market Research
April 03, 2023 11:00 ET
|
Allied Market Research
Portland, OR, April 03, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global oral antiviral market generated $35.21 billion in 2021, and is estimated to...
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
December 19, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor...
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
November 01, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
September 14, 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral...
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
September 13, 2022 08:00 ET
|
Pardes Biosciences, Inc
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1...
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel...
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
June 01, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...